CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 2, May/June 2023 72 AFRICA 3. Ziaeian B, Fonarow GC. Epidemiology and etiology of heart failure. Nat Rev Cardiol 2016; 13: 368. 4. Geremy A, Jessup M. Understanding heart failure. Heart Fail Clin 2017; 13: 1–19. 5. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 2009; 119(14): 391–479. 6. Metra M, Carubelli V, Ravera A, et al. Heart failure 2016: still more questions than answers. Int J Cardiol 2017; 227: 766–777. 7. Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States; rational, design and preliminary from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005; 149: 209–216. 8. Lappas G, Fu M, Rosengren A. Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail 2014; 16: 737–742. 9. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011; 37(4): 619–626. 10. Rahman T, Majumder A, Rahman A. Clinical presentation of heart failure patients admitted in National Institute of Cardiovascular Diseases, Dhaka. J Med 2014; 15: 18–22. 11. Dzudie A, Milo O, Edwards CA, et al. Prognostic significance of ECG abnormalities for mortality risk in acute heart failure: insight from the Sub-Saharan Africa Survey of Heart Failure (THESUS-HF). J Card Fail 2014; 20: 45. 12. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 232–240. 13. Epidemiological and evolutionary characteristics of heart failure in patients with left bundle branch block – a Moroccan center-based study. J Saudi Heart Assoc 2015; 27: 1–9. 14. Berkovitch A, Maor A, Sabbag A, et al. Factors for acute heart failure hospitalization and long-term survival. Medicine (Baltimore) 2015; 94(52): e23–30. 15. Dokainish H, Teo K, Zhu J, et al. INTER-CHF investigators. Heart failure in Africa, Asia, the Middle East and South America: The INTERCHF study. Int J Cardiol 2016; 204: 133–141. 16. Ponikowski P, Voors AA, Anker SD. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). J Heart Fail 2016; 18(8): 891–975. 17. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18: 613–625. 18. Savarese G,, Lars H. Global public health burden of heart failure. Card Fail Rev 2017; 3(1): 7–11. 19. Maggioni AP, Dahlström U, Filippatos G, et al. EURO observational research programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12(10): 1076–1084. 20. O’Connor CM. High heart failure readmission rates. Is it the health system’s fault? J Am Coll Cardiol 2017; 5(5): 393. 21. Ponikowski P Anker S, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014; 1: 4–25. 22. Gheorghiade M, Flaherty JD, Fonarow GC, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol 2011; 151: 69–75. 23. Gajanana D, Shah M, Junpapart P, et al. Mortality in systolic heart failure revisited: ischemic versus non-ischemic cardiomyopathy. Int J Cardiol 2016; 224: 15–17. 24. Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and nonfatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009; 11: 281–229. 25. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 170–177. 26. Taneva B, Caparoska D. The impact of treatment with beta-blockers upon mortality in chronic heart failure patients. Maced J Med Sci 2016; 4(1): 94–97.
RkJQdWJsaXNoZXIy NDIzNzc=